1092977-61-1
1092977-61-1
Chemical Structure
Evenamide
Synonym(s): NW-3509
- CAS No.: 1092977-61-1
- Formula:C16H26N2O2
- Molecular Weight:278.39
IUPAC Name: 2-((3-butoxyphenethyl)amino)-N,N-dimethylacetamide
InChIKey: GRHBODILPPXVKN-UHFFFAOYSA-N
SMILES: O=C(N(C)C)CNCCC1=CC=CC(OCCCC)=C1
Biological Activity: Evenamide (NW-3509) is an orally available voltage-gated sodium channel (VGSC) blocker (Ki=0.4 µM) for the research of schizophrenia. Evenamide shows efficacy in a broad spectrum of rodent models of psychosis, mania, depression, and aggressiveness[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Evenamide | 96.09% | Evenamide (NW-3509) is an orally available voltage-gated sodium channel (VGSC) blocker (Ki=0.4 µM) for the research of schizophrenia. Evenamide shows efficacy in a broad spectrum of rodent models of psychosis, mania, depression, and aggressiveness. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Valentina Zuliani, et al. Advances in Design and Development of Sodium Channel Blockers. Ion Channels and Their Inhibitors pp 79-115.
- [2]. Faravelli, et al. P.3.f.022 Evenamide (formerly NW-3509) targets new mechanisms, and represents a new approach to the management of untreated symptoms in schizophrenia.
